MIRA Pharmaceuticals Announces New Preclinical Study Results Highlighting Potential Advantages Of Novel Oral Ketamine Analog Ketamir-2 For Neurological And Neuropsychiatric Disorders
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals has announced new preclinical study results for its novel oral ketamine analog, Ketamir-2, which shows potential advantages for treating neurological and neuropsychiatric disorders.
July 22, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals announced promising preclinical results for Ketamir-2, a novel oral ketamine analog, which could be beneficial for neurological and neuropsychiatric disorders.
The announcement of positive preclinical results for Ketamir-2 suggests potential future success in clinical trials, which could lead to new treatment options and revenue streams for MIRA Pharmaceuticals. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100